Journal article

A randomised controlled trial comparing fibreoptic-guided tracheal intubation through two supraglottic devices: Ambu (R) AuraGain (TM) laryngeal mask and LMA (R) Fastrach (TM)

G Preece, I Ng, K Lee, P Mezzavia, R Krieser, DL Williams, O Stewart, R Segal

ANAESTHESIA AND INTENSIVE CARE | AUSTRALIAN SOC ANAESTHETISTS | Published : 2018

Abstract

The Ambu®AuraGain™ laryngeal mask (LM) (Ambu A/S, Ballerup, Denmark) is one of the few readily available second-generation supraglottic airway devices (SADs) that offer a conduit for fibreoptic-guided endotracheal intubation. We aimed to compare fibreoptic intubation through this device with the LMA® (laryngeal mask airway) Fastrach™ (Teleflex Medical, Co. Westmeath, Ireland), which has been a recommended dedicated rescue device for the management of the unanticipated difficult airway. This randomised controlled trial compared a previously described fibreoptic score in 116 patients with no known airway pathology, who had asleep fibreoptic endotracheal intubation via either the AuraGain LM or..

View full abstract